For decades, Alzheimer's research has focused on clearing amyloid plaques from the brain. But new drugs that successfully remove plaques have proven clinically "underwhelming", leaving the field searching for alternative approaches.Stanford neurologist Katrin Andreasson has spent twenty years pursuing a different path—investigating how aging triggers an energy crisis in the brain's immune and support cells. Her work reveals that inflammation and metabolic dysfunction in microglia and astrocytes may be the real drivers of Alzheimer's pathology. Most remarkably, her recent research—supported by the Knight Initiative for Brain Resilience here at the Wu Tsai Neurosciences Institute—shows that targeting inflammation in the peripheral immune system—outside the brain entirely—can restore memory in mouse models of the disease. While human trials are still needed, Andreasson's findings offer fresh hope and demonstrate the critical importance of supporting curiosity-driven science, even when it challenges prevailing dogma.Learn More:Alzheimer's Association honors Katrin AndreassonResearch links age-related inflammation, microglia and Alzheimer’s DiseaseQ&A: How the aging immune system impacts brain healthRethinking Alzheimer's: Could it begin outside the brain?Why new Alzheimer's drugs may not work for patientsParkinson’s comes in many forms. New biomarkers may explain why.Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. We want to hear from your neurons! Email us at at [email protected] Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related